Tracon Pharmaceuticals Inc., of San Diego, presented preclinical data from two separate liver fibrosis models in a poster, “Endoglin Antibody Reduces the NAFLD Activity Score in the STAM Model of NASH and Reduces Liver Fibrosis Following Carbon Tetrachloride Treatment.”